Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [68Ga]MLN6907
MLN6907 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| [68Ga]MLN6907 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| [68Ga]MLN6907 | DRUG | IV Administration of \[68Ga\]MLN6907 on Day 1 |
Inclusion Criteria Each patient must meet all of the following inclusion criteria to be enrolled in the study: * Male or female patients 18 years or older. * Must be diagnosed with colorectal cancer (CRC) with liver metastasis and eligible and scheduled for resection of liver metastases as part of...
MLN6907 is an investigational small molecule imaging agent developed by Takeda Pharmaceutical Company Limited. It is being studied for imaging of solid gastrointestinal tumors, including metastatic colorectal cancer. MLN6907 is also known as [68Ga]MLN6907. It has completed a Phase 1 clinical trial and is not approved for commercial use.
MLN6907 is used for imaging of solid gastrointestinal tumors. It is being developed as a diagnostic imaging agent to visualize these tumors in patients. The Phase 1 study enrolled patients with metastatic colorectal cancer, a type of solid gastrointestinal tumor, to evaluate the agent's imaging properties.
MLN6907 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. Takeda is the sponsor of the clinical program evaluating MLN6907 for imaging of solid gastrointestinal tumors.
MLN6907 is in Phase 1 clinical development. It has completed one Phase 1 trial and is investigational, meaning it has not been approved by the FDA or any regulatory agency for commercial use. The completed trial enrolled 20 patients and was conducted in the United States and Mexico.
MLN6907 has been studied in one completed Phase 1 clinical trial, NCT02056015, titled A Phase I Study of MLN6907 in Patients With Metastatic Colorectal. The trial enrolled 20 patients with imaging of solid gastrointestinal tumors, was uncontrolled, and took place in the United States and Mexico.
Yes, MLN6907 is also known as [68Ga]MLN6907. The bracketed notation indicates the drug is labeled with gallium-68, a radioactive isotope used in positron emission tomography imaging. Both names refer to the same investigational imaging agent developed by Takeda for solid gastrointestinal tumors.